

# CITATION REPORT

List of articles citing

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

DOI: 10.1161/01.CIR.94.3.258  
Circulation, 1996, 94, 258-65.

**Source:** <https://exaly.com/paper-pdf/86225187/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
724	Dilated Cardiomyopathy: Changing Pathophysiological Concepts and Mechanisms of Dysfunction. <b>1985</b> , 2, 64-72		
723	The New Paradigm for Coronary Artery Disease: Altering Risk Factors, Atherosclerotic Plaques, and Clinical Prognosis. <b>1996</b> , 71, 957-965		4
722	The New Paradigm for Coronary Artery Disease: Altering Risk Factors, Atherosclerotic Plaques, and Clinical Prognosis. <b>1996</b> , 71, 957-965		25
721	Effect of ACE inhibitors on endothelial dysfunction: unanswered questions and implications for further investigation and therapy. <b>1996</b> , 10, 469-73		9
720	Effects of sulphhydryl- and non-sulphhydryl-containing ACE inhibitors on left ventricular relaxation in the isolated guinea pig heart. <b>1997</b> , 5, 265-75		16
719	Non-invasive assessment of endothelial function. <b>1997</b> , 77, 297-8		16
718	Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event. <b>1997</b> , 15, 793-8		33
717	The heart and conduit vessels in hypertension. <b>1997</b> , 81, 1247-71		6
716	Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus. <b>1997</b> , 53, 1081-105		20
715	Impairment of endothelium-dependent relaxation of rabbit aortas by cigarette smoke extract--role of free radicals and attenuation by captopril. <b>1997</b> , 131, 195-202		135
714	Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease. <b>1997</b> , 62 Suppl 2, S101-9		24
713	Chronic Heart Failure. <b>1997</b> , 1, 185-196		3
712	Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance. <b>1997</b> , 54 Suppl 5, 1-11		7
711	ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. <b>1997</b> , 54 Suppl 5, 12-22		38
710	Endothelial function and bradykinin in humans. <b>1997</b> , 54 Suppl 5, 42-7		44
709	Do ACE inhibitors provide protection for the heart in the clinical setting of acute myocardial infarction?. <b>1997</b> , 54 Suppl 5, 48-58		6
708	Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?. <b>1997</b> , 54 Suppl 5, 59-70		28

707	Coronary endothelial function in health and disease. <b>1997</b> , 53 Suppl 1, 20-9	8
706	ACE inhibition accelerates endothelial regrowth in vivo: a possible explanation for the benefit observed with ACE inhibitors following arterial injury. <b>1997</b> , 231, 577-81	13
705	The place of angiotensin-converting enzyme inhibition after acute myocardial infarction. <b>1997</b> , 134, S25-30	3
704	Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?. <b>1997</b> , 134, S31-47	11
703	Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. <b>1997</b> , 30, 108-12	69
702	Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators. <b>1997</b> , 30, 400-5	37
701	Endothelial dysfunction: does it matter? Is it reversible?. <b>1997</b> , 30, 325-33	535
700	Vasculoprotective and Cardioprotective Mechanisms of Angiotensin-Converting Enzyme Inhibition: The Homeostatic Balance Between Angiotensin II and Nitric Oxide. <b>1997</b> , 20, II-18	5
699	Endothelial Dysfunction in Essential Hypertension. <b>1997</b> , 20, II-26	22
698	Therapeutic Interventions in Endothelial Dysfunction: Endothelium as a Target Organ. <b>1997</b> , 20, II-45	10
697	Potential Role of Angiotensin-Converting Enzyme Inhibition in Myocardial Ischemia and Current Clinical Trials. <b>1997</b> , 20, II-58	4
696	Assessment of endothelial function--go with the flow. <b>1997</b> , 27, 637-8	
695	New insights into the treatment of hypertension. <b>1997</b> , 24, 978-81	
694	Progress in Interventional Cardiology. <b>1997</b> , 10, 93-96	
693	Regulation of vascular tone and endothelial function and its alterations in cardiovascular disease. <b>1997</b> , 11, 531-560	2
692	The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. <b>1997</b> , 79, 24-8	21
691	Improved endothelial function with angiotensin-converting enzyme inhibitors. <b>1997</b> , 79, 29-32	17
690	Response of symptomatic myocardial ischemia in ischemic cardiomyopathy to intensive vasodilator therapy. <b>1997</b> , 80, 212-4	1

689	Management of patients with chronic stable angina at low risk for serious cardiac events. <b>1997</b> , 79, 24-30	13
688	Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND Investigators. Trial on Reversing Endothelial Dysfunction. <b>1997</b> , 80, 1594-7	47
687	Role of endothelial dysfunction in coronary artery disease and implications for therapy. <b>1997</b> , 80, 111-161	102
686	How to standardize vasomotor tone in serial studies based on quantitation of coronary dimensions?. <b>1998</b> , 14, 357-72	11
685	Influence of smoking status on progression of endothelial dysfunction. TREND Investigators. Trial on Reversing Endothelial Dysfunction. <b>1998</b> , 21, 331-4	26
684	Clinical implications of endothelial dysfunction. <b>1998</b> , 21, 795-9	40
683	Restoration of nitric oxide function in human hyperlipidaemia, congestive heart failure and liver cirrhosis. <b>1998</b> , 25, 645-52	3
682	Nitric oxide in atherosclerosis: vascular protector or villain?. <b>1998</b> , 25, S34-41	42
681	Factors involved in the maintenance of endothelial function. <b>1998</b> , 82, 3S-4S	32
680	Potential mechanisms for the effect of angiotensin-converting enzyme inhibitors on endothelial dysfunction: the role of nitric oxide. <b>1998</b> , 82, 8S-10S	4
679	Bradykinin and the therapeutic actions of angiotensin-converting enzyme inhibitors. <b>1998</b> , 82, 11S-13S	13
678	Effects of antihypertensive agents on endothelial dysfunction: rationale for the brachial artery normalization of forearm function study. <b>1998</b> , 82, 34S-36S	8
677	Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. <b>1998</b> , 82, 9R-14R	140
676	Hypertension, heart failure, and endothelial function. <b>1998</b> , 82, 20S-22S	9
675	The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: potential role in myocardial ischemia. <b>1998</b> , 82, 23S-27S	16
674	Factors involved in the maintenance of endothelial function. <b>1998</b> , 82, S3-S4	23
673	Potential mechanisms for the effect of angiotensin-converting enzyme inhibitors on endothelial dysfunction: The role of nitric oxide. <b>1998</b> , 82, S8-S10	4
672	Bradykinin and the therapeutic actions of angiotensin-converting enzyme inhibitors. <b>1998</b> , 82, S11-S13	5

671	Hypertension, heart failure, and endothelial function. <b>1998</b> , 82, S20-S22	6
670	The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: Potential role in myocardial ischemia. <b>1998</b> , 82, S23-S27	6
669	Effects of antihypertensive agents on endothelial dysfunction: Rationale for the brachial artery normalization of forearm function study. <b>1998</b> , 82, S34-S36	7
668	New insight into coronary endothelial dysfunction: role of endothelin. <b>1998</b> , 131, 300-5	17
667	Preliminary experience with stent-supported coronary angioplasty in long narrowings using the long Freedom Force stent: acute and six-month clinical and angiographic results in a series of 27 consecutive patients. <b>1998</b> , 43, 163-7	7
666	[Therapeutic options for improvement of myocardial perfusion in coronary atherosclerosis]. <b>1998</b> , 23, 116-29	2
665	Effect of angiotensin-converting enzyme inhibition with perindopril and beta-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects. <b>1998</b> , 47, 28-33	17
664	Beneficial effects of angiotensin-converting enzyme inhibitors during acute revascularization. <b>1998</b> , 66, 487-492	8
663	Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized, double-blind study. <b>1998</b> , 31, 1330-5	67
662	Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. <b>1998</b> , 32, 1969-74	92
661	Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors. <b>1998</b> , 32, 1962-8	31
660	Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. <b>1998</b> , 73, 1133-40	62
659	Effect of angiotensin-converting enzyme inhibitor dosing interval on functional parameters in patients with chronic heart failure. <b>1998</b> , 135, 237-41	6
658	Current medical therapy for advanced heart failure. <b>1998</b> , 135, S231-48	38
657	New concepts and paradigms in cardiovascular medicine: the noninvasive management of coronary artery disease. <b>1998</b> , 104, 2S-17S	145
656	Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. <b>1998</b> , 105, 27S-31S	77
655	Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. <b>1998</b> , 105, 32S-39S	290
654	Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease. <b>1998</b> , 105, 40S-47S	31

653	The cardiovascular dysmetabolic syndrome. <b>1998</b> , 105, 77S-82S	84
652	Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. <b>1998</b> , 137, 197-203	101
651	Improvement of coronary vasodilatation capacity through single LDL apheresis. <b>1998</b> , 139, 173-8	101
650	The role of lipid-lowering therapy in multiple risk factor management. <b>1998</b> , 56 Suppl 1, 1-7; discussion 33	5
649	Abnormal vascular responses in human chronic cardiac failure are both endothelium dependent and endothelium independent. <b>1998</b> , 80, 141-5	43
648	Endoluminal vessel reconstruction by stent placement in patients with obstructive coronary artery disease who are poor surgical candidates. <b>1998</b> , 80, 355-8	
647	Influence of prior ACE inhibitor therapy on morbidity and mortality following acute myocardial infarction. <b>1998</b> , 32, 1141-6	6
646	Endothelial dysfunction: implications for therapy of cardiovascular diseases. <b>1998</b> , 32, 459-70	27
645	The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. <b>1998</b> , 7, 176-83	132
644	Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. <b>1998</b> , 16, 447-56	77
643	The role of endothelium in human hypertension. <b>1998</b> , 7, 203-9	34
642	Role of nitric oxide in cardiovascular disease: focus on the endothelium. <b>1998</b> , 44, 1809-1819	237
641	Enhanced endothelial vasoreactivity in endurance-trained older men. <b>1999</b> , 87, 2136-42	64
640	Effect of 17beta-estradiol in hypercholesterolemic rabbits with severe endothelial dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>1999</b> , 276, H1788-94	5.2 9
639	Coronary microvascular disease in humans. <b>1999</b> , 40, 97-108	18
638	Angiotensin II and oxidized LDL: an unholy alliance creating oxidative stress. <b>1999</b> , 14, 2585-9	20
637	The salt dilemma: some answers, many questions. <b>1999</b> , 170, 178-80	
636	What is causing your patient's sexual dysfunction? Uncovering a connection with hypertension and antihypertensive therapy. <b>1999</b> , 106, 149-52, 155-7	12

635	L-Arginine: a novel therapy for coronary artery disease?. <b>1999</b> , 8, 1785-1793	11
634	Angiotensin converting enzyme inhibition and arterial endothelial function in adults with Type 1 diabetes mellitus. <b>1999</b> , 16, 62-6	35
633	Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. <b>1999</b> , 245, 315-27	75
632	Dilated cardiomyopathy: changing pathophysiological concepts and mechanisms of dysfunction. <b>1999</b> , 14, 64-74	14
631	Reactive oxygen species and the control of vasomotor tone. <b>1999</b> , 1, 102-8	32
630	Mechanism by which quinapril improves vascular function in coronary artery disease. <b>1999</b> , 83, 327-31	68
629	Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. <b>1999</b> , 83, 332-6	22
628	Prognostic utility of myocardial viability assessment. <b>1999</b> , 83, 696-702, A7	31
627	Maintenance of blood pressure control and left ventricular performance with small doses of enalapril. <b>1999</b> , 83, 719-23	1
626	Effect of enalaprilat on nitric oxide activity in coronary artery disease. <b>1999</b> , 84, 1-6	22
625	Antiatherosclerotic activity of drugs in relation to nitric oxide function. <b>1999</b> , 375, 157-76	23
624	Nitric oxide modulates captopril-mediated angiotensin-converting enzyme inhibition in porcine iliac arteries. <b>1999</b> , 385, 21-7	6
623	Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. <b>1999</b> , 64, 673-7	89
622	Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients. <b>1999</b> , 18, 211-9	44
621	Higher levels of antioxidant defenses in enalapril-treated versus non-enalapril-treated hemodialysis patients. <b>1999</b> , 34, 445-55	54
620	Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin. <b>1999</b> , 33, 796-804	54
619	A comparison of the cold pressor test and the diving test on coronary and systemic hemodynamics in patients with and without coronary artery disease. <b>1999</b> , 71, 7-15	2
618	Cardiac production of angiotensin II and its pharmacologic inhibition: effects on the coronary circulation. <b>1999</b> , 74, 503-13	7

617	Medical treatment of the aorta. II. <b>1999</b> , 17, 717-37, viii-ix	3
616	Improving the adverse cardiovascular prognosis of type 2 diabetes. <b>1999</b> , 74, 171-80	68
615	Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. <b>1999</b> , 33, 1163-73	46
614	Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. <b>1999</b> , 33, 1506-11	154
613	Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. <b>1999</b> , 34, 83-9	97
612	Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function. <b>1999</b> , 34, 140-5	76
611	Assessment and treatment of endothelial dysfunction in humans. <b>1999</b> , 34, 631-8	340
610	Coronary artery apoptosis in experimental hypercholesterolemia. <b>1999</b> , 142, 317-25	31
609	Vitamin E ingestion does not improve arterial endothelial dysfunction in older adults. <b>1999</b> , 143, 193-9	69
608	Effect of insulin resistance on the endothelial vasomotor function of the coronary artery of nondiabetic patients. <b>1999</b> , 63, 589-92	4
607	Evidence based cardiology: emerging approaches in preventing cardiovascular disease. <b>1999</b> , 318, 1337-41	23
606	Cardiac Production of Angiotensin II and Its Pharmacologic Inhibition: Effects on the Coronary Circulation. <b>1999</b> , 74, 503-513	12
605	Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions. <b>1999</b> , 17, 547-53	33
604	Low-density lipoprotein-independent effects of statins. <b>1999</b> , 10, 543-59	166
603	Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. <b>1999</b> , 39, 111-8	35
602	Endothelial dysfunctions: common denominators in vascular disease. <b>2000</b> , 3, 453-67	36
601	Effect of ACE inhibition and angiotensin AT1 receptor blockade on renal and blood pressure response to L-arginine in humans. <b>2000</b> , 18, 51-9	13
600	Early angiotensin converting enzyme inhibitor therapy enhances the benefits of late coronary artery reperfusion on infarct expansion. <b>2000</b> , 11, 183-9	2



599	Endothelial dysfunctions: common denominators in vascular disease. <b>2000</b> , 11, 9-23	84
598	Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. <b>2000</b> , 18, 363-74	119
597	Regulation of the angiotensin AT1 receptor by hypercholesterolaemia. <b>2000</b> , 2, 223-8	14
596	Flow-mediated dilatation. <b>2000</b> , 50, 397-404	191
595	Evaluation of endothelium-dependent vasodilation in the human peripheral circulation. <b>2000</b> , 20, 440-8	75
594	Exhaled nitric oxide during incremental and constant workload exercise in chronic cardiac failure. <b>2000</b> , 30, 181-7	9
593	ACE-inhibition modulates some endothelial functions in healthy subjects and in normotensive type 1 diabetic patients. <b>2000</b> , 30, 853-60	30
592	Why do antioxidants fail to provide clinical benefit?. <b>2000</b> , 1, 38-40	32
591	The role of myocardial perfusion imaging in vascular endothelial dysfunction. <b>2000</b> , 7, 180-4	18
590	Better preservation of endothelial function and decreased activation of the fetal renin-angiotensin pathway with the use of pulsatile flow during experimental fetal bypass. <b>2000</b> , 120, 770-7	36
589	The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. <b>2000</b> , 21, 257-85	66
588	Effect of atenolol and celiprolol on acetylcholine-induced coronary vasomotion in coronary artery disease. <b>2000</b> , 85, 172-7	14
587	Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of RENal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). <b>2000</b> , 86, 635-8	54
586	Effect of angiotensin-converting enzyme inhibitor therapy on 30-day outcome in patient > or = 65 years of age with chronic congestive heart failure. <b>2000</b> , 86, 1151-3, A9	6
585	Overview of the relationship between ischemia and congestive heart failure. <b>2000</b> , 23, IV4-8	25
584	Endothelial function as a therapeutic target in coronary artery disease. <b>2000</b> , 2, 303-7	7
583	Improvement of endothelial dysfunction as a surrogate endpoint in the treatment of hypertension. <b>2000</b> , 2, 227-9	3
582	Effects of antihypertensive therapy on hypertensive vascular disease. <b>2000</b> , 2, 280-8	30

581	Vasopeptidase inhibition: a new direction in cardiovascular treatment. <b>2000</b> , 2, 384-91	7
580	Angiotensin converting enzyme inhibitors: are they preferred first-line therapy?. <b>2000</b> , 2, 392-7	
579	Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. <b>2000</b> , 2, 64-70	57
578	Stable Angina Pectoris. <b>2000</b> , 2, 161-172	3
577	Syndrome X. <b>2000</b> , 2, 73-82	3
576	Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues. <b>2000</b> , 278, R572-7	93
575	Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. <b>2000</b> , 14, 271-8	139
574	ACE inhibitors are better than AT(1) receptor blockers (ARBs) controversies in heart failure. <b>2000</b> , 2, 237-40	2
573	Pharmacologic Regulation of the Renin-Angiotensin System: Physiologic and Pathologic Effects. <b>2000</b> , 16, 138-146	1
572	The endothelium: a new target for therapy. <b>2000</b> , 5, 49-53	85
571	Acute effects of ACE inhibition on coronary endothelial dysfunction. <b>2000</b> , 1, 361-4	13
570	Exercise--toning up the endothelium?. <b>2000</b> , 342, 503-5	45
569	Endothelial dysfunction: the role and impact of the renin-angiotensin system. <b>2000</b> , 84 Suppl 1, i20-2:discussion i50	38
568	Current medical therapy for advanced heart failure. <b>2000</b> , 29, 16-32	29
567	The multiple actions of angiotensin II in atherosclerosis. <b>2000</b> , 93, 65-77	145
566	Plasma renin activity in the emergency department and its independent association with acute myocardial infarction. <b>2000</b> , 13, 855-63	27
565	Angiotensin AT1 receptor over-expression in hypercholesterolaemia. <b>2000</b> , 32, 386-9	69
564	Infarct Size as Assessed by Peak Enzyme Levels is Reduced in Patients Who are Using Angiotensin-Converting Enzyme Inhibitors at the Onset of Infarction. <b>2000</b> , 20, 415-423	1

563	Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. <b>2000</b> , 152, 511-8	66
562	Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. <b>2000</b> , 36, 438-43	190
561	Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. <b>2000</b> , 36, 1461-6	107
560	Endothelium: a new target for cardiovascular therapeutics. <b>2000</b> , 35, 67-70	15
559	Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). <b>2000</b> , 35, 60-6	323
558	Effect of exercise on coronary endothelial function in patients with coronary artery disease. <b>2000</b> , 342, 454-60	972
557	Cardiomyopathy and heart failure in diabetes. <b>2001</b> , 30, 1031-46	16
556	Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates. <b>2001</b> , 158, 165-71	50
555	Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. <b>2001</b> , 37, 470-4	13
554	Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. <b>2001</b> , 37, 1565-70	74
553	A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. <b>2001</b> , 37, 1757-64	60
552	A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. <b>2001</b> , 37, 1858-63	65
551	Angiotensin-converting enzyme inhibition is associated with reduced troponin release in non-ST-elevation acute coronary syndromes. <b>2001</b> , 38, 724-8	23
550	Anti-ischemic effects of angiotensin- converting enzyme inhibition in hypertension. <b>2001</b> , 38, 1116-22	7
549	Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. <b>2001</b> , 38, 1089-95	49
548	Maintaining the endothelium: preventive strategies for vessel integrity. <b>2001</b> , 4, 28-37	1
547	Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. <b>2001</b> , 33, 395-403	36
546	Formulating clinical strategies for angiotensin antagonism: a review of preclinical and clinical studies. <b>2001</b> , 110, 471-80	10

545	Noninvasive tests of vascular function and structure: why and how to perform them. <b>2001</b> , 141, 694-703	76
544	The endothelium: a gynecological and obstetric point of view. <b>2001</b> , 94, 180-5	4
543	Pathophysiology of vascular endothelium and circulating platelets: implications for coronary revascularisation and treatment. <b>2001</b> , 79, 265-75	10
542	Angiotensin-converting enzyme inhibitors. <b>2001</b> , 56, 13-75	44
541	High tissue affinity angiotensin-converting enzyme inhibitors improve endothelial function and reduce infarct size. <b>2001</b> , 72, 548-53; discussion 553-4	33
540	Arteriosclerosis. <b>2001</b> , 8, 2267-2273	
539	[Progress in the knowledge on endothelial dysfunction and its application in clinical practice]. <b>2001</b> , 54, 211-7	2
538	Mejorí de la funci3 endotelial al reducir las concentraciones lipídicas en pacientes con hipercolesterolemia y arterias coronarias normales. <b>2001</b> , 54, 685-692	7
537	Antiatherosclerotic effects of ACE inhibitors: where are we now?. <b>2001</b> , 1, 315-20	7
536	Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients. <b>2001</b> , 16, 1465-70	21
535	Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2001</b> , 280, H2248-54	5.2 5
534	Beyond remodeling: a new paradigm for angiotensin-converting enzyme inhibitors following myocardial infarction. <b>2001</b> , 37 Suppl 1, S31-4	3
533	Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging. <b>2001</b> , 19, 1403-9	28
532	Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. <b>2001</b> , 37 Suppl 1, S21-30	46
531	Low-pressure deployment of stents: short- and long-term outcome. <b>2001</b> , 12, 313-6	1
530	Current strategies and perspectives for correcting endothelial dysfunction in atherosclerosis. <b>2001</b> , 38 Suppl 2, S35-41	17
529	Coronary vascular endothelial function and myocardial ischemia: why should we worry about endothelial dysfunction?. <b>2001</b> , 12, 475-84	11
528	Oxidative stress and vascular damage in hypertension. <b>2001</b> , 10, 247-55	109

527	Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. <b>2001</b> , 19, 547-51	66
526	Anti-ischemic effects of angiotensin-converting enzyme inhibitors: a future therapeutic perspective. <b>2001</b> , 37 Suppl 1, S3-9	14
525	The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?. <b>2001</b> , 10, 597-601	19
524	Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors. <b>2001</b> , 38 Suppl 3, S3-11	14
523	Role of nitric oxide in regulation of coronary blood flow in response to increased metabolic demand in dogs with pacing-induced heart failure. <b>2001</b> , 65, 827-33	6
522	Reversal of endothelial dysfunction in humans. <b>2001</b> , 12, 463-73	13
521	The renin angiotensin system as a risk factor for coronary artery disease. <b>2001</b> , 3, 117-24	33
520	Antioxidants and endothelial dysfunction in hyperlipidemia. <b>2001</b> , 3, 53-60	50
519	Vasopeptidase inhibition and endothelial function in hypertension. <b>2001</b> , 3 Suppl 2, S6-14	1
518	No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months. <b>2001</b> , 2, 99-105	3
517	Dose response of ACE inhibitors: implications of the SECURE trial. <b>2001</b> , 2, 155-159	8
516	Polymorphisms in the renin-angiotensin system and endothelium-dependent vasodilation in normotensive subjects. <b>2001</b> , 21, 343-9	10
515	Aspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system. <b>2001</b> , 31, 476-88	43
514	Careful screening to target interventions to prevent sudden cardiac death. <b>2001</b> , 28, 219-22	
513	Soy protein diet significantly improves endothelial function and lipid parameters. <b>2001</b> , 24, 711-6	32
512	The role of ACE-inhibitors in patients with coronary artery disease. <b>2001</b> , 15, 103-5	
511	The EUROPA trial: design, baseline demography and status of the substudies. <b>2001</b> , 15, 169-79	34
510	The role of nitric oxide in the failing heart. <b>2001</b> , 6, 105-18	49

509	Impairment of myocardial blood flow reserve in patients with asymptomatic left ventricular dysfunction: effects of ACE-inhibition with perindopril. <b>2001</b> , 17, 353-9	9
508	Quinapril with high affinity to tissue angiotensin-converting enzyme reduces restenosis after percutaneous transcatheter coronary intervention. <b>2001</b> , 15, 323-9	7
507	Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound. <b>2001</b> , 87, 443-5, A6	23
506	Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. <b>2001</b> , 87, 542-6	122
505	The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. <b>2001</b> , 87, 1058-63	192
504	Effect of quinapril versus nitrendipine on endothelial dysfunction in patients with systemic hypertension. <b>2001</b> , 87, 1414-6	14
503	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. <b>2001</b> , 88, 1L-20L	164
502	Why vascular biology matters. <b>2001</b> , 88, 5K-9K	72
501	Effect of lipid-lowering agents, angiotensin-converting enzyme inhibitors, and calcium antagonists on coronary disease risk. <b>2001</b> , 88, 21M-25M	6
500	Acute administration of nicotine impairs the hypotensive responses to bradykinin in rats. <b>2001</b> , 413, 241-6	5
499	What is the optimal medical management of ischemic heart failure?. <b>2001</b> , 43, 433-55	19
498	Diabetes. <b>2001</b> , 59, 159-72	4
497	What is the optimal medical management of ischaemic heart failure?. <b>2001</b> , 59, 135-58	5
496	Review: Interaction among angiotensin II, nitric oxide and oxidative stress. <b>2001</b> , 2, S59-S63	5
495	Hypertension syndrome and cardiovascular events. High blood pressure is only one risk factor. <b>2001</b> , 110, 29-36	12
494	Anti-ischemic potential of drugs related to the renin-angiotensin system. <b>2001</b> , 37 Suppl 1, S11-20	24
493	Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. <b>2001</b> , 24, 2091-6	200
492	Diabetic heart disease: clinical considerations. <b>2001</b> , 85, 463-9	24

491	Diabetes and endothelial dysfunction: a clinical perspective. <b>2001</b> , 22, 36-52	476
490	Relation between blood pressure after an acute coronary event and subsequent cardiovascular risk. <b>2002</b> , 88, 555-8	1
489	NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. <b>2002</b> , 4, 899-914	172
488	Rapid detection of polymorphisms of the nitric oxide cascade. <b>2002</b> , 40, 341-4	5
487	Prevention of diabetes in cardiovascular studies: implications for the aetiology of type 2 diabetes. <b>2002</b> , 2, 384-389	
486	Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management. <b>2002</b> , 3, 96-102	3
485	Endothelial dysfunction, angiotensin-converting enzyme inhibitors and calcium antagonists. <b>2002</b> , 16 Suppl 1, S34-7	9
484	Endomyocardial nitric oxide synthase and the hemodynamic phenotypes of human dilated cardiomyopathy and of athlete's heart. <b>2002</b> , 55, 270-8; discussion 225-8	20
483	Ongoing trials involving angiotensin-converting enzyme inhibitors. <b>2002</b> , 11, 1633-43	1
482	Blockade of endothelial enzymes: new therapeutic targets. <b>2002</b> , 16 Suppl 1, S100-3	10
481	Review: Managing the diabetic patient with angina. <b>2002</b> , 2, 169-175	
480	Exaggerated endothelin release in response to acute mental stress in patients with intermittent claudication. <b>2002</b> , 53, 383-90	26
479	Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. <b>2002</b> , 25, 2249-55	63
478	. <b>2002</b> , 9, 53-57	6
477	Use of Angiotensin-Converting Enzyme Inhibitors to Prevent Cardiovascular Disease. <b>2002</b> , 5, 61-67	
476	Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. <b>2002</b> , 20, 71-8	91
475	Quinapril prevents restenosis after coronary stenting in patients with angiotensin-converting enzyme D allele. <b>2002</b> , 66, 311-6	23
474	Comparison of nitric oxide production in response to carbachol between macrovascular and microvascular cardiac endothelial cells. <b>2002</b> , 66, 511-5	6

473	Nitric oxide-dependent vasodilation in human subjects. <b>2002</b> , 359, 186-200	40
472	Vascular and cardiac benefits of angiotensin receptor blockers. <b>2002</b> , 113, 409-18	108
471	Beyond blood pressure: the endothelium and atherosclerosis progression. <b>2002</b> , 15, 115S-122S	120
470	Early dysfunction and long-term improvement in endothelium-dependent vasodilation in the infarct-related artery after thrombolysis. <b>2002</b> , 40, 257-65	31
469	Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. <b>2002</b> , 160, 339-44	16
468	Use of angiotensin-converting enzyme inhibitors in patients with diabetes and coronary artery disease. <b>2002</b> , 27, 6-36	10
467	Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. <b>2002</b> , 62, 265-84	131
466	Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. <b>2002</b> , 62, 339-85	13
465	Papel de la agiotensina II en el desarrollo ateroesclerótico: efecto de su bloqueo. <b>2002</b> , 19, 311-320	
464	Efectos de irbesartán y losartán en conejos hipercolesterolémicos. <b>2002</b> , 14, 230-238	
463	Lowering of blood pressure improves endothelial dysfunction by increase of nitric oxide production in hypertensive rats. <b>2002</b> , 25, 455-60	23
462	Flow-mediated dilatation in human circulation: diagnostic and therapeutic aspects. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2002</b> , 282, H1-5	5.2 65
461	Effects of cilazapril on endothelial function and pulmonary hypertension in patients with congestive heart failure. <b>2002</b> , 43, 667-74	8
460	Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits. <b>2002</b> , 442, 99-106	5
459	Endothelial function. From vascular biology to clinical applications. <b>2002</b> , 90, 40L-48L	360
458	Oxidative stress and endothelial dysfunction in heart failure. <b>2002</b> , 8, 165-72	44
457	ACE inhibitors and survival of hemodialysis patients. <b>2002</b> , 40, 1023-9	152
456	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. <b>2002</b> , 4, 363-72	28



455	Effects of antihypertensive therapy on sexual activity in hypertensive men. <b>2002</b> , 4, 202-10	54
454	Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?. <b>2002</b> , 4, 290-7	1
453	Invasive assessment of the coronary circulation: intravascular ultrasound and Doppler. <b>2002</b> , 53, 561-75	7
452	Captopril and quinapril reduce reactive oxygen species. <b>2002</b> , 32, 732-7	20
451	Central role of the AT(1)-receptor in atherosclerosis. <b>2002</b> , 16 Suppl 3, S26-33	60
450	Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis. <b>2002</b> , 82, 825-32	26
449	Angiotensin II and nitric oxide interaction. <b>2002</b> , 7, 347-58	58
448	Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications. <b>2003</b> , 15, 217-25	7
447	Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. <b>2003</b> , 8, 71-86	112
446	Use of ACE Inhibitors for Secondary Prevention. <b>2003</b> , 5, 51-61	1
445	The L-arginine-nitric oxide pathway in hypertension. <b>2003</b> , 5, 80-6	35
444	Treatment of Raynaud's phenomenon: new insights and developments. <b>2003</b> , 5, 168-74	28
443	Erectile dysfunction in the cardiac patient. <b>2003</b> , 4, 466-71	16
442	Smoking and endothelial function. <b>2003</b> , 45, 443-58	117
441	Effects of angiotensin II on vascular endothelial cells: formation of receptor-mediated reactive nitrogen species. <b>2003</b> , 65, 1189-97	34
440	Prognostic value of endothelial function. <b>2003</b> , 91, 19H-24H	127
439	Endothelial dysfunction and inflammation: what is the link?. <b>2003</b> , S45-9	50
438	Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction. <b>2003</b> , S54-7	13

- 437 Pathophysiological implications of insulin resistance on vascular endothelial function. **2003**, 20, 255-68 198
- 436 Antihypertensive drug-associated sexual dysfunction: a prescription analysis-based study. **2003**, 12, 203-12 11
- 435 Hipercolesterolemia y disfunci3n endotelial: mecanismos implicados. **2003**, 20, 116-126
- 434 [Analysis of differences in flow-mediated dilation in relation to the treatment of coronary patients]. **2003**, 56, 128-36 2
- 433 Estudio comparativo de efectividad y tolerabilidad de quinapril 40 mg frente a la combinaci3n de quinapril 20 mg e hidroclorotiazida 12,5 mg en el tratamiento de la hipertensi3n arterial ligera-moderada. **2003**, 20, 246-251
- 432 [Cardiovascular syndrome X and endothelial dysfunction]. **2003**, 56, 181-92 14
- 431 [Atheroma plaque stabilization: a new concept based on the dynamic biology of atherosclerosis]. **2003**, 121, 583-7 6
- 430 Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. **2003**, 42, 2049-59 35
- 429 Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. **2003**, 169, 155-8 73
- 428 Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. **2003**, 41, 420-5 27
- 427 Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes. **2003**, 41, 235-305 16
- 426 Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. **2003**, 41, 1373-9 30
- 425 Statins, skin, and the search for a test of endothelial function. **2003**, 42, 78-80 13
- 424 Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. **2003**, 42, 698-704 39
- 423 Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. **2003**, 145, 993-8 22
- 422 Endothelial dysfunction: clinical strategies for treating oxidant stress. **2003**, 146, 218-26 64
- 421 Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction. **2003**, 146, 549-54 35
- 420 Update on therapy for heart failure. **2003**, 115, 480-8 16

419	Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. <b>2003</b> , 115, 473-9		45
418	Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. <b>2003</b> , 162, 1985-93		53
417	Effects of low-dose combination therapy with an angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study. <b>2003</b> , 64, 715-24		4
416	The clinical implications of endothelial dysfunction. <b>2003</b> , 42, 1149-60		1219
415	Demographics and concomitant disorders in heart failure. <b>2003</b> , 362, 147-58		118
414	ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. <b>2003</b> , 3, 351-60		8
413	Nitric Oxide Signaling and Clinical Alternatives to Nitric Oxide. <b>2003</b> , 7, 239-252		1
412	Plaque stabilisation in acute coronary syndromes: clinical considerations. <b>2003</b> , 89, 1268-72		4
411	Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients. <b>2003</b> , 4, 119-23		11
410	The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease. <b>2003</b> , 8, 273-8		23
409	Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). <i>Circulation</i> , <b>2003</b> , 107, 422-8	16.7	125
408	Angiotensin subtype 1 rReceptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor. <b>2003</b> , 307, 1171-8		61
407	Mechanisms of oxidative stress and vascular dysfunction. <b>2003</b> , 79, 195-199; quiz 198-200		119
406	Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type 1a receptor. <b>2003</b> , 42 Suppl 1, S67-70		25
405	Captopril restores endothelium-dependent relaxation of rat aortic rings after exposure to homocysteine. <b>2003</b> , 42, 566-72		16
404	Nitric oxide in diabetes mellitus. <b>2003</b> , 21, 1081-3		4
403	Diabetes mellitus and coronary artery disease: therapeutic considerations. <b>2003</b> , 5, 119-28		4
402	Impact of myocardial angiotensin-converting enzyme activity on coronary vascular resistance and serum brain natriuretic peptide concentration in coronary bypass surgery. <b>2003</b> , 67, 379-83		2

401	Angiotensin-converting enzyme inhibitor promotes coronary collateral circulation in patients with coronary artery disease. <b>2003</b> , 67, 535-8		15
400	New methods to evaluate endothelial function: Evaluation of endothelial function by hemoglobin-nitric oxide complex using electron paramagnetic resonance spectroscopy. <b>2003</b> , 93, 417-22		4
399	Myocardial fibrosis blunts nitric oxide synthase-related preload reserve in human dilated cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2003</b> , 284, H10-6	5.2	10
398	Evaluation of systemic blood NO dynamics by EPR spectroscopy: HbNO as an endogenous index of NO. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2003</b> , 285, H589-96	5.2	31
397	In vivo measurement of coronary circulation angiotensin-converting enzyme activity in humans. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2003</b> , 284, H17-22	5.2	2
396	Statins in the Primary Prevention of Atherosclerosis-Related Events. <b>2004</b> , 53-92		
395	A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension. <b>2004</b> , 45, 623-35		21
394	ACE inhibitors for patients with vascular disease without left ventricular dysfunction--may they rest in PEACE?. <b>2004</b> , 351, 2115-7		74
393	Angiotensin II and Nitric Oxide Interaction. <b>2004</b> , 137-148		1
392	Endothelial function and oxidative stress. <b>2004</b> , 11, 123-32		119
391	Impaired brachial artery endothelium dependent flow mediated dilation in systemic lupus erythematosus: preliminary observations. <b>2004</b> , 13, 590-3		37
390	Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes. <b>2004</b> , 5, 33-8		13
389	Nitric Oxide, Atherosclerosis and the Clinical Relevance of Endothelial Dysfunction. <b>2004</b> , 55-70		
388	Impaired endothelium-dependent and -independent vasodilation in elderly patients with chronic heart failure. <b>2004</b> , 6, 901-8		18
387	Tonic levels of angiotensin II reduce tonic levels of vascular nitric oxide even in salt-replete man. <b>2004</b> , 5, 84-8		2
386	Dose-dependent effect of captopril on aortic reactivity of streptozotocin-diabetic rats. <b>2004</b> , 31, 342-7		2
385	Angiotensin-converting enzyme inhibitors (ACEIs) and age-related maculopathy (ARM): cross-sectional findings from the Blue Mountains Eye Study. <b>2004</b> , 82, 298-303		5
384	Candesartan cilexetil protects cavernous tissue in spontaneously hypertensive rats. <b>2004</b> , 16, 305-12		12

383	Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. <b>2004</b> , 18, 781-8	57
382	The metabolic syndrome: an emerging health epidemic in women. <b>2004</b> , 46, 321-36	55
381	The clinical use of angiotensin-converting enzyme inhibitors. <b>2004</b> , 47, 116-30	59
380	Protective effect of enalapril on vascular reactivity of the rat aorta. <b>2004</b> , 40, 301-7	15
379	Manipulation of the renin angiotensin system in peripheral arterial disease. <b>2004</b> , 28, 573-82	10
378	Assessing the prognostic value of coronary endothelial function in patients referred for a first coronary angiogram. <b>2004</b> , 94, 1063-7	9
377	Effects of cyclooxygenase inhibition on endothelial function in hypertensive patients treated with angiotensin-converting enzyme inhibitors. <b>2004</b> , 27, 523-7	8
376	Angiotensin-converting enzyme gene polymorphism in Behçet's disease. <b>2004</b> , 23, 142-6	24
375	Aspirin in cardiovascular disorders. What is the optimum dose?. <b>2004</b> , 4, 151-8	14
374	Cardiac syndrome X. Diagnosis, pathogenesis and management. <b>2004</b> , 4, 179-94	49
373	Papel de los inhibidores de la enzima conversora de la angiotensina en los pacientes con riesgo cardiovascular. <b>2004</b> , 204, 592-593	1
372	Coronary artery disease and prevention of heart failure. <b>2004</b> , 88, 1209-35	17
371	Nitric oxide, angiotensin II, and hypertension. <b>2004</b> , 24, 366-78	87
370	Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. <b>2004</b> , 43, 629-34	75
369	Are cardiovascular disease and osteoporosis directly linked?. <b>2004</b> , 34, 779-807	28
368	Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats. <b>2004</b> , 23, 729-36	27
367	Effect of ramipril on postrevascularization prevalence of angina and quality of life. <b>2004</b> , 95, 159-65	1
366	The role of coronary endothelial function testing in patients suspected for angina pectoris. <b>2004</b> , 96, 123-9	10

365	Long-term effects of quinapril with high affinity for tissue angiotensin-converting enzyme after coronary intervention in Japanese. <b>2004</b> , 147, 662-8		13
364	Insulin resistance and the endothelium. <b>2004</b> , 117, 109-17		180
363	The effect of intravenous quinaprilat on plasma cytokines and hemodynamic variables during cardiac surgery. <b>2004</b> , 18, 53-8		15
362	Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. <b>2004</b> , 177, 147-53		12
361	Angiotensin receptor blockade decreases markers of vascular inflammation. <b>2004</b> , 44, 335-9		49
360	Beneficial effects of quinaprilat on coronary vasomotor function, endothelial oxidative stress, and endothelin activation after human heart transplantation. <b>2004</b> , 77, 1859-65		23
359	Renin-angiotensin system as a therapeutic target in managing atherosclerosis. <b>2004</b> , 11, 44-53		34
358	ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2004</b> , 286, H1425-32	5.2	49
357	New FACES to the renin-angiotensin system. <b>2005</b> , 20, 91-5		36
356	High glucose levels abolish antiatherosclerotic benefits of ACE inhibition in alloxan-induced diabetes in rabbits. <b>2005</b> , 45, 295-300		10
355	Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. <b>2005</b> , 23, 233-46		529
354	Vascular but not cardiac remodeling is associated with superoxide production in angiotensin II hypertension. <b>2005</b> , 23, 1737-43		28
353	von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. <b>2005</b> , 128, 2355-62		65
352	The kallikrein-kinin system: current and future pharmacological targets. <b>2005</b> , 99, 6-38		328
351	Captopril restores endothelium-dependent relaxation induced by advanced oxidation protein products in rat aorta. <b>2005</b> , 46, 803-9		13
350	Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?. <b>2005</b> , 28, 551-5		17
349	Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. <b>2005</b> , 257, 263-71		28
348	Pharmacology of vascular endothelium. Delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw. <b>2005</b> , 272, 2956-67		9

347	Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. <b>2005</b> , 39, 1184-90	82
346	Long-term effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: a pilot study. <b>2005</b> , 2, 207-12	27
345	Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. <b>2005</b> , 42, 125-40	30
344	Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis. <b>2005</b> , 7, 61-7	44
343	Lack of association between Chlamydia Pneumoniae serology and endothelial dysfunction of coronary arteries. <b>2005</b> , 3, 12	3
342	Pathogenesis of Raynaud's phenomenon. <b>2005</b> , 44, 587-96	290
341	Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function. <b>2005</b> , 91, 1053-7	18
340	High angiotensin II responsiveness is associated with decreased endothelium-dependent relaxation in human arteries. <b>2005</b> , 6, 145-50	5
339	Fármacos antihipertensivos y aterogénesis. <b>2005</b> , 17, 16-24	
338	Management of the patient with chest pain and a normal coronary angiogram. <b>2005</b> , 23, 559-68, viii	5
337	New considerations relating to class effect with angiotensin-converting enzyme inhibitors--the PEACE study. <b>2005</b> , 7, 188-93	2
336	The effect of combined Angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. <b>2005</b> , 24, 1033-8	51
335	Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient. <b>2005</b> , 79, 1081-9	14
334	Endothelial Dysfunction in the Metabolic Syndrome. <b>2005</b> , 321-338	
333	Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. <b>2005</b> , 3, 15-29	50
332	Optimal medical management of peripheral arterial disease. <b>2006</b> , 40, 312-27	52
331	Clinical assessment of endothelial function. <b>2006</b> , 13, 367-74	5
330	Novel therapies targeting vascular endothelium. <b>2006</b> , 13, 411-21	45

329	Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk. <b>2006</b> , 22 Suppl B, 72B-80B	114
328	Coagulation and atherothrombotic disease. <b>2006</b> , 186, 240-59	73
327	Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. <b>2006</b> , 47, 1576-83	126
326	Cardiac syndrome X and endothelial dysfunction: new concepts in prognosis and treatment. <b>2006</b> , 119, 560-6	57
325	Endothelial nitric oxide synthase G894T gene polymorphism in Chilean subjects with coronary artery disease and controls. <b>2006</b> , 371, 102-6	39
324	Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. <b>2006</b> , 387, 1521-33	116
323	Optimal vascular protection: a case for combination antihypertensive therapy. <b>2006</b> , 9, 35-41	5
322	Nitric oxide mechanisms in the pathogenesis of global risk. <b>2006</b> , 8, 31-8; quiz 40	25
321	Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. <b>2006</b> , 8, 2-16	38
320	Targeting nitric oxide with drug therapy. <b>2006</b> , 8, 40-52	36
319	Alterations in angiotensin converting enzyme during rodent aortic aneurysm formation. <b>2006</b> , 132, 69-73	5
318	Endothelial function is impaired in patients with primary antiphospholipid syndrome. <b>2006</b> , 118, 455-61	33
317	Protection of endothelial function: targets for nutritional and pharmacological interventions. <b>2006</b> , 47 Suppl 2, S136-50; discussion S172-6	47
316	Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. <b>2006</b> , 24, S39-43	40
315	Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. <b>2006</b> , 24, S45-50	64
314	Angiotensin II type 1 receptor antagonism improves endothelial vasodilator function in L-NAME-induced hypertensive rats by a kinin-dependent mechanism. <b>2006</b> , 24, 95-102	15
313	Effects of oral beraprost sodium, a prostaglandin I2 analogue, on endothelium dependent vasodilatation in the forearm of patients with coronary artery disease. <b>2006</b> , 33, 381-7	11
312	The protective effect of captopril on nicotine-induced endothelial dysfunction in rat. <b>2006</b> , 99, 237-45	34



311	Improved coronary vasodilatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment. <b>2006</b> , 10, 510-7	25
310	Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?. <b>2006</b> , 62, 633-44	130
309	Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in Nomega-nitro-L-arginine methyl ester-treated rats. <b>2006</b> , 29, 369-74	19
308	Antihypertensive treatment and endothelium-dependent venodilation in sleep-disordered breathing. <b>2006</b> , 10, 115-22	5
307	ACE inhibition in secondary prevention: are the results controversial?. <b>2006</b> , 95, 61-7	19
306	Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. <b>2006</b> , 61, 491-5	114
305	Angiotensin-converting enzyme (ACE) dimerization is the initial step in the ACE inhibitor-induced ACE signaling cascade in endothelial cells. <b>2006</b> , 69, 1725-32	40
304	The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. <b>2006</b> , 11, 251-7	46
303	Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells. <b>2006</b> , 316, 1153-8	17
302	Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. <b>2007</b> , 21, 770-9	22
301	Endothelial nitric oxide synthase gene: prospects for treatment of heart disease. <b>2007</b> , 8, 1723-34	39
300	Endothelial function, arterial stiffness and lipid lowering drugs. <b>2007</b> , 11, 1143-60	27
299	Angiotensin-converting enzyme inhibitors and coronary heart disease prevention. <b>2007</b> , 8, 13-22	17
298	Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. <b>2007</b> , 112, 417-28	319
297	Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. <b>2007</b> , 25, 361-6	50
296	Claims in advertisements for antihypertensive drugs in a Dutch medical journal. <b>2007</b> , 25, 713-22	9
295	Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. <b>2007</b> , 25, 785-91	65
294	Interaction between beta2 adrenergic receptor polymorphisms determines the extent of isoproterenol-induced vasodilatation ex vivo. <b>2007</b> , 17, 803-11	6

293	Enalapril and losartan restored blood pressure and vascular reactivity in intrauterine undernourished rats. <b>2007</b> , 80, 782-7	35
292	AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. <b>2007</b> , 194, 439-45	25
291	Renin-angiotensin system and cardiovascular risk. <b>2007</b> , 369, 1208-19	507
290	The impact of insulin resistance on endothelial function, progenitor cells and repair. <b>2007</b> , 4, 103-11	40
289	Medical Treatment of Stable Angina. <b>2007</b> , 911-936	
288	ACE inhibition in hypertension: focus on perindopril. <b>2007</b> , 7, 303-17	15
287	The Endothelium in Hypertension: Assessment and Clinical Aspects of Micro- and Macrovascular Function. <b>2007</b> , 151-156	1
286	Angiotensin-Converting Enzyme Inhibitors. <b>2007</b> , 985-1001	
285	Endothelial Dysfunction is Associated with Future Stroke in Patients Who Undergo Percutaneous Coronary Intervention. <b>2007</b> , 37, 497	
284	Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. <b>2007</b> , 56, 3837-46	95
283	Role of PET in the evaluation and understanding of coronary physiology. <b>2007</b> , 14, 589-603	49
282	The effects of atorvastatin therapy on endothelial function in patients with coronary artery disease. <b>2007</b> , 5, 51	8
281	The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus. <b>2007</b> , 9, 617-29	8
280	Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. <b>2007</b> , 9, 781-91	108
279	Atherogenesis: the role of inflammation and infection. <b>2007</b> , 50, 535-46	74
278	Pharmacogenomics of renin angiotensin system inhibitors in coronary artery disease. <b>2007</b> , 21, 121-32	3
277	ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. <b>2007</b> , 21, 269-79	34
276	Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes. <b>2007</b> , 21, 375-88	11

275	Einfluss antihypertensiver Medikamente auf die Endothelfunktion. <b>2007</b> , 3, 430-438	
274	Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. <b>2008</b> , 25, 1798-806	29
273	The angiotensin II type 2 receptor: what is its clinical significance?. <b>2008</b> , 10, 188-93	26
272	Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients?. <b>2008</b> , 10, 286-92	3
271	Optimal risk factor modification and medical management of the patient with peripheral arterial disease. <b>2008</b> , 71, 475-89	41
270	L-arginine preferentially dilates stenotic segments of coronary arteries thereby increasing coronary flow. <b>2008</b> , 264, 237-44	6
269	Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation. <b>2008</b> , 28, 565-72	1
268	VASCULAR INFLAMMATION AND ATHEROGENESIS ARE ACTIVATED VIA RECEPTORS FOR PAMPs AND SUPPRESSED BY REGULATORY T CELLS. <b>2008</b> , 5, 125-142	60
267	Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. <b>2008</b> , 10 Suppl 2, S3	21
266	Diagnosis and management of scleroderma peripheral vascular disease. <b>2008</b> , 34, 89-114; vii	48
265	Raynaud's phenomenon: pathogenesis and management. <b>2008</b> , 59, 633-53	113
264	Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. <b>2008</b> , 122, 85-90	64
263	Determinants of endothelial function in asymptomatic subjects with and without the metabolic syndrome. <b>2008</b> , 197, 375-82	20
262	Pulsatile stretch induces release of angiotensin II and oxidative stress in human endothelial cells: effects of ACE inhibition and AT1 receptor antagonism. <b>2008</b> , 30, 616-27	26
261	Treatment of hypertension in heart failure with preserved ejection fraction: role of the kidney. <b>2008</b> , 4, 479-503	
260	Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. <b>2008</b> , 10, 1631-74	131
259	Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension. <b>2008</b> , 15, 149-55	20
258	Surrogate markers for atherosclerosis in overweight subjects with atherogenic dyslipidemia: the GEMS project. <b>2008</b> , 59, 484-92	12

257	Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. <b>2008</b> , 51, 454-9		31
256	Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. <b>2008</b> , 327, 324-31		12
255	Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. <b>2008</b> , 31, 271-9		41
254	Pharmacological Interventions to Prevent Vascular Endothelial Dysfunction: Future Directions. <b>2008</b> , 54, 1-16		14
253	Peripheral artery disease: potential role of ACE-inhibitor therapy. <i>Vascular Health and Risk Management</i> , <b>2008</b> , 4, 1179-87	4-4	12
252	Role of oxidative stress and nitric oxide in atherothrombosis. <b>2008</b> , 13, 5323-44		127
251	Association of urinary N-domain Angiotensin I-converting enzyme with plasma inflammatory markers and endothelial function. <b>2008</b> , 14, 429-35		5
250	Endothelial Function as a Possible Significant Determinant of Cardiac Function during Exercise in Patients with Structural Heart Disease. <b>2009</b> , 2009, 927385		2
249	Clinical effects of calcium channel blocker and Angiotensin converting enzyme inhibitor on endothelial function and arterial stiffness in patients with angina pectoris. <b>2009</b> , 24, 223-31		20
248	Endothelium function assessment with radial pulse wave signals. <b>2009</b> , 2009, 3035-8		
247	A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. <b>2009</b> , 30, 1590-7		72
246	Angiotensin-converting enzyme inhibitors and atherosclerotic plaque: a key role in the cardiovascular protection of patients with coronary artery disease. <b>2009</b> , 11, E9-E16		5
245	The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. <b>2009</b> , 2009, 752406		65
244	Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease. <b>2009</b> , 11, 260-5		18
243	Subclinical atherosclerosis and endothelial dysfunction in young South-Asian patients with systemic lupus erythematosus. <b>2009</b> , 28, 1259-65		23
242	Cardiovascular outcomes and angiotensin converting enzyme inhibitors: beyond blood pressure control. Editorial to: "Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?" by Remme et al. <b>2009</b> , 23, 109-11		0
241	Increased expression of endothelin ET(B) and angiotensin AT(1) receptors in peripheral resistance arteries of patients with suspected acute coronary syndrome. <b>2009</b> , 24, 393-8		9
240	Cardiovascular risk factors and collateral artery formation. <b>2009</b> , 39, 1036-47		23

239	Treatment strategies for peripheral artery disease. <b>2009</b> , 10, 1571-86	8
238	Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. <b>2009</b> , 53, 323-30	239
237	The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function. <b>2009</b> , 116, 301-14	30
236	Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. <b>2009</b> , 5, 1337-47	6
235	The Triad of Endothelial Dysfunction, Cardiovascular Disease, and Erectile Dysfunction: Clinical Implications. <b>2009</b> , 8, 58-66	14
234	Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results. <b>2009</b> , 25, e236-40	12
233	Risk prediction in cardiovascular disease: the prognostic significance of endothelial dysfunction. <b>2009</b> , 25 Suppl A, 15A-20A	49
232	Single-pill combination of amlodipine and valsartan in the management of hypertension. <b>2009</b> , 10, 1979-94	16
231	Effects of bradykinin on venous capacitance in health and treated chronic heart failure. <b>2009</b> , 116, 443-50	5
230	Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease. <b>2010</b> , 99, 787-94	27
229	Endothelial dysfunction: a strategic target in the treatment of hypertension?. <b>2010</b> , 459, 995-1004	124
228	Risk Factors for Heart Failure in Young Adults. <b>2010</b> , 4, 128-135	
227	Vascular endothelial function and hypertension: insights and directions. <b>2010</b> , 12, 448-55	273
226	Progression of cardiovascular damage: the role of renin-angiotensin system blockade. <b>2010</b> , 105, 10A-20A	68
225	HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study. <b>2010</b> , 99, 457-9	9
224	The endothelial cell in health and disease: its function, dysfunction, measurement and therapy. <b>2010</b> , 22, 77-90	41
223	Myocardial Blood Flow Measurement: Evaluating Coronary Pathophysiology and Monitoring Therapy. <b>2010</b> , 506-527	1
222	Prolonged fasting does not increase oxidative damage or inflammation in postweaned northern elephant seal pups. <b>2010</b> , 213, 2524-30	60

221	Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. <b>2010</b> , 107, 10190-5	90
220	Plasma plasminogen activator inhibitor 1 (PAI-1) and P-selectin levels in urgent hypertension: effect of single dose captopril and nifedipine on fibrinolytic activity. <b>2010</b> , 32, 347-51	5
219	Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. <b>2010</b> , 33, 11-21	70
218	Impaired relaxation of cerebral arteries in the absence of elevated salt intake in normotensive congenic rats carrying the Dahl salt-sensitive renin gene. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2010</b> , 299, H1865-74	5.2 22
217	When and why do heart attacks occur? Cardiovascular triggers and their potential role. <b>2010</b> , 38, 144-52	9
216	Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. <b>2010</b> , 3, 623-40	263
215	Sporting events affect spectators' cardiovascular mortality: it is not just a game. <b>2010</b> , 123, 972-7	35
214	Oxidants and Endothelial Dysfunction. <b>2010</b> , 243-274	4
213	Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. <b>2010</b> , 33, 796-801	28
212	Imagine how many lives you save: angiotensin-converting enzyme inhibition for atherosclerotic vascular disease in the present era of risk reduction. <b>2011</b> , 12, 883-97	7
211	Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. <b>2011</b> , 15, 1957-97	605
210	Should all patients be treated with an angiotensin-converting enzyme inhibitor after coronary artery bypass graft surgery? The impact of angiotensin-converting enzyme inhibitors, statins, and $\beta$ -blockers after coronary artery bypass graft surgery. <b>2011</b> , 162, 836-43	12
209	In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). <b>2011</b> , 162, 678-84	140
208	Angiotensin-converting enzyme inhibition promotes coronary angiogenesis in the failing heart of Dahl salt-sensitive hypertensive rats. <b>2011</b> , 17, 1041-50	25
207	Total saponins of panax ginseng inhibiting human endothelium cells' damages induced by angiotensin II via AT1 receptor. <b>2011</b> , 138, 439-44	5
206	Effects of ramiprilat-coated stents on neointimal hyperplasia, inflammation, and arterial healing in a porcine coronary restenosis model. <b>2011</b> , 41, 535-41	6
205	Flow-Mediated Vasodilatation and Intima-Media Thickness in Patients with Coexisting Heart Failure and Diabetes Receiving Medical Therapy. <b>2011</b> , 1, 38-52	2
204	Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester. <b>2011</b> , 57, 559-67	45

203	Association between brachial-ankle pulse wave velocity and endothelium-dependent and -independent coronary vasomotor function. <b>2011</b> , 38, 34-41	4
202	Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. <b>2011</b> , 164, 213-23	187
201	Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women: a Women's Ischemia Syndrome Evaluation (WISE) ancillary study. <b>2011</b> , 34, 483-7	34
200	Assessment of Endothelial Function Using Arterial Pressure Signals. <b>2011</b> , 64, 223-232	21
199	Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers. <b>2011</b> , 67, 365-370	17
198	Effects of antihypertensive treatment on endothelial function. <b>2011</b> , 13, 276-81	45
197	Urinary proteomics in cardiovascular disease: Achievements, limits and hopes. <b>2011</b> , 5, 222-32	9
196	35 MHz quartz crystal microbalance and surface plasmon resonance studies on the binding of angiotensin converting enzyme with lisinopril. <b>2011</b> , 26, 3240-5	8
195	Modern treatment of patients at risk: still a HOPE for ACE inhibitors?. <b>2011</b> , 12, 839-43	4
194	Angiotensin II binding to angiotensin I-converting enzyme triggers calcium signaling. <b>2011</b> , 57, 965-72	29
193	Where are we heading with noninvasive clinical vascular physiology? Why and how should we assess endothelial function?. <b>2011</b> , 2011, 870132	11
192	Use of angiotensin-converting enzyme inhibitors and cardiovascular outcomes following primary vascular surgery: a nationwide propensity score matched follow-up study. <b>2012</b> , 46, 515-23	7
191	Targeting endothelial dysfunction in vascular complications associated with diabetes. <b>2012</b> , 2012, 750126	46
190	Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. <b>2012</b> , 344, 268-73	49
189	The renin-angiotensin system, bone marrow and progenitor cells. <b>2012</b> , 123, 205-23	54
188	Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. <b>2012</b> , 220, 265-8	81
187	The role of renin angiotensin system intervention in stage B heart failure. <b>2012</b> , 8, 225-36	3
186	Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?. <b>2012</b> , 26, 1130-44	12

185	Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. <b>2012</b> , 23, 1717-24	65
184	Papel de la angiotensina II en el proceso aterosclerótico. <b>2012</b> , 24, 92-101	
183	Systemic Vascular Disease. <b>2012</b> , 347-359	
182	Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patients. <b>2012</b> , 60, 887-94	38
181	Coronary endothelial dysfunction distal to stent of first-generation drug-eluting stents. <b>2012</b> , 5, 966-73	34
180	The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. <b>2012</b> , 108, 1089-96	57
179	Nitric oxide synthases: regulation and function. <b>2012</b> , 33, 829-37, 837a-837d	2229
178	The assessment of endothelial function: from research into clinical practice. <i>Circulation</i> , <b>2012</b> , 126, 753-67.7	749
177	Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention. <b>2012</b> , 14, 433-42	21
176	Relation between previous angiotensin-converting enzyme inhibitor use and in-hospital outcomes in acute coronary syndromes. <b>2012</b> , 109, 332-6	3
175	Emotional stressors trigger cardiovascular events. <b>2012</b> , 66, 631-9	61
174	Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension. <b>2012</b> , 14, 85-91	19
173	Impact of kinins in the treatment of cardiovascular diseases. <b>2012</b> , 135, 94-111	62
172	Quantitative PET/CT measures of myocardial flow reserve and atherosclerosis for cardiac risk assessment and predicting adverse patient outcomes. <b>2013</b> , 15, 344	26
171	Oral sarpogrelate can improve endothelial dysfunction as effectively as oral cilostazol, with fewer headaches, in active young male smokers. <b>2013</b> , 28, 578-82	10
170	Approaches for non-invasive assessment of endothelial function: focus on peripheral arterial tonometry. <b>2013</b> , 21, 214-8	19
169	The bumpy road to evidence: why many research findings are lost in translation. <b>2013</b> , 34, 3329-35	13
168	Effect of Ω3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in patients with a previous myocardial infarction: a randomised controlled trial. <b>2013</b> , 3, e003054	9



167	Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. <b>2013</b> , 125, 154-68	36
166	Myocardial ischemia and angiotensin-converting enzyme inhibition: comparison of ischemia during mental and physical stress. <b>2013</b> , 75, 815-21	8
165	NO-dependent endothelial dysfunction in type II diabetes is aggravated by dyslipidemia and hypertension, but can be restored by angiotensin-converting enzyme inhibition and weight loss. <b>2013</b> , 50, 486-97	22
164	Erectile dysfunction in heart failure patients: a critical reappraisal. <b>2013</b> , 1, 177-91	16
163	A bumpy and winding but right path to domestic drug-eluting coronary stents. <b>2013</b> , 43, 645-54	4
162	Effects of Low Dose versus High Dose Statin Therapy on the Changes of Endothelial Function and Carotid Intima-Media Thickness in Patients with Variant Angina. <b>2013</b> , 21, 58-63	9
161	ROS, Notch, and Wnt signaling pathways: crosstalk between three major regulators of cardiovascular biology. <b>2014</b> , 2014, 318714	47
160	Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. <b>2014</b> , 2014, 801269	111
159	Endothelial dysfunction and cardiovascular disease. <b>2014</b> , 2014, 291-308	152
158	A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. <b>2014</b> , 22, 11-9	43
157	Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis. <b>2014</b> , 43, 772-7	18
156	El factor de crecimiento del hepatocito disminuye la expresi3n vascular de mediadores inflamatorios y la hipertensi3n en ratas espont3neamente hipertensas. <b>2014</b> , 33, 87-95	
155	Pharmacological approaches to coronary microvascular dysfunction. <b>2014</b> , 144, 283-302	20
154	Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches. <b>2014</b> , 144, 253-67	73
153	Vascular Endothelial Function. <b>2014</b> , 1-37	
152	Effects of angiotensin-converting enzyme inhibitors and beta blockers on clinical outcomes in patients with and without coronary artery obstructions at angiography (from a Register-Based Cohort Study on Acute Coronary Syndromes). <b>2014</b> , 113, 1628-33	28
151	Renin-angiotensin system inhibitors and troponin elevation in spinal surgery. <b>2014</b> , 21, 1133-40	4
150	Endothelial Function in Hypertension: Victim or Culprit?. <b>2015</b> , 17, 651-4	39

149	Endothelial dysfunction and coronary artery disease: a state of the art review. <b>2015</b> , 23, 119-29	29
148	Prognostic significance of endothelial dysfunction in patients undergoing percutaneous coronary intervention in the era of drug-eluting stents. <b>2015</b> , 15, 102	8
147	Vascular endothelial dysfunction and pharmacological treatment. <b>2015</b> , 7, 719-41	120
146	Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches. <b>2015</b> , 30, 1213-25	151
145	Endothelial dysfunction as a predictor of cardiovascular disease in type 1 diabetes. <b>2015</b> , 6, 679-92	50
144	Medical Treatment of Stable Angina. <b>2015</b> , 421-459	
143	Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases. <b>2015</b> , 751-806	1
142	A Fractal Analysis of the Detection of Biomarkers for Different Diseases on Biosensor Surfaces. <b>2015</b> , 597-652	
141	Vascular Endothelial Function. <b>2015</b> , 89-120	4
140	Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy. <b>2015</b> , 242, 295-302	13
139	Effect of preoperative angiotensin-converting enzyme inhibitor on the outcome of coronary artery bypass graft surgery. <b>2015</b> , 47, 788-95	16
138	Positron-emitting myocardial blood flow tracers and clinical potential. <b>2015</b> , 57, 588-606	23
137	Meta-analysis of the effects of preoperative renin-angiotensin system inhibitor therapy on major adverse cardiac events in patients undergoing cardiac surgery. <b>2015</b> , 47, 958-66	22
136	Clinical Application of Myocardial Blood Flow Quantification in CAD Patients. <b>2016</b> , 2, 84-93	5
135	Vascular Aging: Implications for Cardiovascular Disease and Therapy. <b>2016</b> , 6,	36
134	Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders. <b>2016</b> , 2016, 3634948	91
133	Associations between parameters of flow-mediated vasodilatation obtained by continuous measurement approaches and the presence of coronary artery disease and the severity of coronary atherosclerosis. <b>2016</b> , 38, 443-50	2
132	Prenatal inflammation-induced NF- $\kappa$ B dyshomeostasis contributes to renin-angiotensin system over-activity resulting in prenatally programmed hypertension in offspring. <b>2016</b> , 6, 21692	18

131	Pathogenesis of Macrovascular Complications in Diabetes. <b>2016</b> , 599-628	1
130	Disfunci3n endotelial tras infarto de miocardio con elevaci3n del segmento ST y evoluci3n a largo plazo: un estudio con tonometr3n arterial perif3rica e hiperemia reactiva. <b>2016</b> , 69, 664-671	3
129	Endothelial dysfunction in human essential hypertension. <b>2016</b> , 34, 1464-72	82
128	Endothelial Dysfunction After ST-segment Elevation Myocardial Infarction and Long-term Outcome: A Study With Reactive Hyperemia Peripheral Artery Tonometry. <b>2016</b> , 69, 664-71	3
127	Drug Treatment of Hypertension: Focus on Vascular Health. <b>2016</b> , 76, 1529-1550	34
126	Myocardial blood flow: Putting it into clinical perspective. <b>2016</b> , 23, 1056-1071	25
125	Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials. <b>2016</b> , 30, 189-98	12
124	Angiotensin-Converting Inhibitors and Angiotensin II Receptor Blockers and Longitudinal Change in Percent Emphysema on Computed Tomography. The Multi-Ethnic Study of Atherosclerosis Lung Study. <b>2017</b> , 14, 649-658	29
123	Antioxidant therapy for management of oxidative stress induced hypertension. <b>2017</b> , 51, 428-438	51
122	The Central Role of Endothelial Dysfunction in Cardiorenal Syndrome. <b>2017</b> , 7, 104-117	32
121	Blood pressure normalization via pharmacotherapy improves cutaneous microvascular function through NO-dependent and NO-independent mechanisms. <b>2017</b> , 24,	11
120	In vitro study on binding interaction of quinapril with bovine serum albumin (BSA) using multi-spectroscopic and molecular docking methods. <b>2017</b> , 35, 2211-2223	53
119	Positron Emission Tomography-Determined Hyperemic Flow, Myocardial Flow Reserve, and Flow Gradient-Quo Vadis?. <b>2017</b> , 4, 46	4
118	Relationship between skin blood flow regulation mechanisms and vascular endothelial growth factor in patients with metabolic syndrome. <b>2018</b> , 70, 129-142	1
117	Evaluation of microvascular endothelial function and capillary density in patients with infective endocarditis using laser speckle contrast imaging and video-capillaroscopy. <b>2018</b> , 118, 61-68	3
116	Oxidants and Endothelial Dysfunction. <b>2018</b> , 252-281	1
115	Endothelium and Arterial Hypertension. <b>2018</b> , 429-437	1
114	Clinical Endothelial Dysfunction: Prognosis and Therapeutic Target. <b>2018</b> , 683-697	0

113	Endothelial Function. <b>2018</b> , 13-30		
112	Anti-Inflammatory Treatment. <b>2018</b> , 237-271		
111	The binding of captopril to angiotensin I-converting enzyme triggers activation of signaling pathways. <b>2018</b> , 315, C367-C379		1
110	Exercise (Prong-5). <b>2019</b> , 299-329		
109	Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	55
108	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version. <b>2019</b> , 83, 2084-2184		228
107	Antihypertensive Drugs and Vascular Health. <b>2019</b> , 585-605		
106	Endothelial function in patients with atrial fibrillation. <b>2020</b> , 52, 1-11		11
105	Gallic Acid Attenuates Angiotensin II-Induced Hypertension and Vascular Dysfunction by Inhibiting the Degradation of Endothelial Nitric Oxide Synthase. <b>2020</b> , 11, 1121		8
104	Role of endothelial dysfunction in determining angina after percutaneous coronary intervention: Learning from pathophysiology to optimize treatment. <b>2020</b> , 63, 233-242		2
103	What Is the Role of Assessing Ischemia to Optimize Therapy and Outcomes for Patients with Stable Angina and Non-obstructed Coronary Arteries?. <b>2021</b> , 1		1
102	Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review. <b>2021</b> , 78, 1352-1371		31
101	Dyslipidemia and Angiotensin II and Atherogenesis. <b>2006</b> , 143-162		1
100	ACE inhibitors and angiotensin II receptor antagonists. <b>2005</b> , 407-42		25
99	Protection of endothelial function. <b>2005</b> , 619-44		11
98	Exploring the Difference Between Angiotensin Converting Enzyme Inhibitors and Angiotensin II-Receptor Antagonists. A Focus on Bradykinin. <b>1998</b> , 175-184		1
97	Cardiovascular Disease and Insulin Resistance. <b>2007</b> , 2803-2818		2
96	Viability assessment: clinical applications. <b>2000</b> , 199-227		1

95	Nitric Oxide and Vascular Endothelial Dysfunction. <b>2000</b> , 547-567	7
94	Treatment of Hypertension in the Patient with Cardiovascular Disease * *Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ACS, acute coronary syndromes; AF, atrial fibrillation; MI, myocardial infarction; ARB, angiotensin II type 1 receptor blocker; BB, beta-adrenergic receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; CHD, coronary heart disease; HDL, high density lipoprotein; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; NIDDM, non-insulin dependent diabetes mellitus; NYCT, nocturnal dipping; P, probability; RAAS, renin-angiotensin-aldosterone system; RAS, renin-angiotensin system; SBP, systolic blood pressure; T, treatment; T2DM, type 2 diabetes mellitus; VLDL, very low density lipoprotein; W, weight. <b>2000</b> , 33, 102-106	0
93	Effects of amlodipine on endothelial function in rats with chronic heart failure after experimental myocardial infarction. <b>1997</b> , 30, 683-9	4
92	Benefits of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands. <b>1998</b> , 31 Suppl 2, S27-33	3
91	Divergent effects of different antihypertensive drugs on endothelium-dependent vasodilation in the human forearm. <b>1998</b> , 32, 406-12	17
90	Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression. <b>1999</b> , 33, S17-S29	14
89	Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression. <b>1999</b> , 33 Suppl 3, S17-29	22
88	Enalapril improves arterial elastic properties in rats with myocardial infarction. <b>1999</b> , 34, 102-7	14
87	Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction. <b>1999</b> , 34, 368-73	9
86	Antihypertensive drugs and the sympathetic nervous system. <b>2000</b> , 35, S43-52	21
85	Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. <b>2000</b> , 35, 173-8	170
84	Endothelial dysfunction and coronary risk reduction. <b>1998</b> , 18, 60-7	10
83	Can angiotensin-converting enzyme inhibitors reverse atherosclerosis?. <b>2003</b> , 96, 569-79	8
82	Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries. <b>2003</b> , 548, 893-906	15
81	Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. <b>1997</b> , 100, 678-84	148
80	Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. <b>2006</b> , 116, 1302-9	74
79	Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. <b>2000</b> , 105, 451-8	223
78	Angiotensin II, atherosclerosis, and aortic aneurysms. <b>2000</b> , 105, 1525-6	32

77	Angiotensin-converting enzyme insertion/deletion polymorphism modulates coronary release of tissue plasminogen activator in response to bradykinin. <b>2004</b> , 27, 39-45	12
76	Self-vasodilating ability at the spastic site of patients with vasospastic angina: estimation by acetylcholine delayed phase. <b>2003</b> , 44, 299-311	2
75	B(2)-receptor modulation of the reactivity to phenylephrine and angiotensin II in the carotid artery of normotensive rats after trandolapril treatment. <b>2006</b> , 42, 21-31	3
74	Endothelial and non-endothelial coronary blood flow reserve and left ventricular dysfunction in systemic hypertension. <b>2009</b> , 64, 327-35	8
73	The factors of risk of the development of endothelium dysfunction that people with hereditary atherosclerosis and coronary atherosclerosis have. <b>2002</b> , 1, 45-52	1
72	Endothelial effects of antihypertensive treatment: focus on irbesartan. <i>Vascular Health and Risk Management</i> , <b>2008</b> , 4, 89-101	4.4 32
71	Endothelial function in normal and pathological conditions. <b>2019</b> , 154-159	6
70	Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches. <b>2020</b> , 27, 1052-1080	20
69	The Role of Vasodilator Receptors of Renin-angiotensin System on Nitric Oxide Formation and Kidney Circulation after Angiotensin II Infusion in Renal Ischemia/Reperfusion Rats. <b>2018</b> , 7, 25	1
68	Is reversal of endothelial dysfunction still an attractive target in modern cardiology?. <b>2014</b> , 6, 824-35	16
67	Endothelial Dysfunction and Atherothrombosis. <b>2000</b> , 21-40	
66	Circadian Variation in Myocardial Ischemia and Infarction. <b>2000</b> , 247-261	
65	Drugs in Development: New Agents, New Classes, New Indications. <b>2000</b> , 273-291	
64	The Role of Nitric Oxide in the Failing Heart. <b>2001</b> , 35-48	
63	Clinical Assessment of Endothelial Function. <b>2002</b> , 691-700	
62	Coronary Atherosclerosis: Chronic Coronary Syndromes. <b>2002</b> , 779-820	
61	Coronary Artery Disease and Endothelial Function. <b>2002</b> , 887-912	
60	Hypertension, Diabetes and the Heart. <b>2002</b> , 65-84	

59 The Endothelium in Atherothrombosis. **2003**, 21-40

58 Cardiovascular Disease, Disturbances of Blood Coagulation and Fibrinolysis. **2003**, 118-147

57 Endotheliale Dysfunktion: Mechanismen und prognostische Bedeutung für die Koronare Herzkrankheit. **2004**, 1-28

56 NEP/ACE Inhibitors: Experimental and Clinical Aspects. **2004**, 519-542

55 Exercise Training and Endothelial Function in Patients at Risk for and with Documented Coronary Artery Disease. **2005**, 85-115

54 ACE Inhibition in Heart Failure and Ischaemic Heart Disease. **2007**, 21-54

53 Inhibitors of Angiotensin-Converting Enzyme, Angiotensin II Receptor, Aldosterone, and Renin. **2009**, 112-159

52 Redox Signaling and Vascular Function. **2009**, 473-507

51 Risk Factor Modification in the Management of Critical Limb Ischemia. **2009**, 85-112

50 Cardiovascular Disease, Disturbances of Blood Coagulation and Fibrinolysis. **2010**, 119-148

49 Ultrasound Assessment of Brachial Artery Reactivity. **2011**, 395-410

48 The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes. 635-656 1

47 Drug Discovery and Evaluation: Methods in Clinical Pharmacology. **2011**, 387-421

46 Stabilizing unstable plaque in acute coronary syndromes. **2011**, 338-345

45 Plaque Passivation and Endothelial Therapy. **2011**, 289-298

44 Antihypertensive Drugs and Their Cardioprotective and Renoprotective Roles in the Prevention and Management of Cardiovascular Disease. **2011**, 161-181

43 Organo-protective effects of quinapril: pharmacogenetic aspects. **2011**, 10, 98-101

42 Zofenopril in the treatment of patients with arterial hypertension and stable coronary heart disease: effects on oxidative stress and flowdependent vasodilatation. **2011**, 10, 15-21

- 41 Endothelium Biology. **2012**, 219-237
- 40 ACE inhibitor effects of brachial artery structure and function in patients with arterial hypertension. **2012**, 11, 35-38
- 39 The Endothelium, Cardiovascular Disease, and Therapy. 409-467
- 38 Management of Chronic Coronary Artery Disease. 60-85
- 37 A possible role for hydrochlorothiazide (HCTZ) as "enhancer" of zofenopril activity at the tissue level. **2013**, 1, 6
- 36 Management of Pain. **2013**, 333-342
- 35 Functional vascular study in hypertensive subjects with type 2 diabetes using losartan or amlodipine. **2014**, 103, 51-9 3
- 34 The Vascular Endothelium in Diabetes. 1-29
- 33 Atherosclerosis: Implications of Angiotensin II and the AT-1 Receptor. **1998**, 233-243
- 32 How should future angiographic trials be designed?. **1998**, 119-131
- 31 Role of Cytokines in Septic Cardiomyopathy. **1998**, 185-219
- 30 Coronary Vascular Function in Stable and Unstable Angina. **1998**, 55-66
- 29 The Role of Imaging Techniques in the Diagnosis of Atherosclerosis. **1998**, 67-99
- 28 Angiotensin-Converting Enzyme Inhibitors in Acute Coronary Syndromes. **1999**, 357-382
- 27 Treatment of Patients with Angina and Normal Coronary Arteriograms. **1999**, 195-201
- 26 The Role of Vascular Failure in Heart Failure. **1999**, 15-20
- 25 Endothelial Dysfunction and the Promise of ACE Inhibitors. **1999**, 99, 44-50
- 24 RHEUMATIC DISEASES AND ENDOTHELIAL FUNCTION. *Voprosy Sovremennoi Pediatrii - Current Pediatrics*, **2018**, 17, 126-132 0.5 1



23	Endothelial function, its relation to arterial hypertension and the possibility of its modulation. <i>Vnitřní Lekarství</i> , <b>2018</b> , 64, 762-770		0.3
22	Herz-Kreislauf-Erkrankungen und Störungen von Blutgerinnungs- und Fibrinolysevorgängen. <b>2008</b> , 197-248		
21	Clinical Evidence: Emerging approaches in preventing cardiovascular disease. <i>Western Journal of Medicine</i> , <b>1999</b> , 171, 247-52		3
20	Topical non-iontophoretic application of acetylcholine and nitroglycerin via a translucent patch: a new means for assessing microvascular reactivity. <i>Yale Journal of Biology and Medicine</i> , <b>2006</b> , 79, 1-7	2.4	8
19	Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. <i>Vascular Health and Risk Management</i> , <b>2005</b> , 1, 183-98	4.4	426
18	Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 521-6	4.4	15
17	Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 937-45	4.4	20
16	Endothelial dysfunction in diabetes mellitus. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 853-76	4.4	287
15	Ulster says NO! NO! explosion, resistance and tolerance. Nitric oxide and the actions of organic nitrates. <i>Ulster Medical Journal</i> , <b>1998</b> , 67, 79-90	0.4	4
14	Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma. <i>Clinical Ophthalmology</i> , <b>2007</b> , 1, 217-23	2.5	20
13	CU06-1004 enhances vascular integrity and improves cardiac remodeling by suppressing edema and inflammation in myocardial ischemia-reperfusion injury.. <i>Experimental and Molecular Medicine</i> , <b>2022</b>	12.8	0
12	Mechanisms and Clinical Implications of Endothelium-dependent Vasomotor Dysfunction in Coronary Microvasculature.. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2022</b> ,	5.2	2
11	Antihipertansif ilaçları koroner kollateral gelişimi üzerine etkileri. <i>Ahi Evran Medical Journal</i> ,	0.1	
10	Image_1.jpeg. <b>2020</b> ,		
9	Image_2.jpeg. <b>2020</b> ,		
8	Table_1.docx. <b>2020</b> ,		
7	Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension. <i>Journal of Cardiovascular Development and Disease</i> , <b>2022</b> , 9, 136	4.2	0
6	Inhibitors of the renin-angiotensin-aldosterone system. <b>2013</b> , 119-168		6

5	The Endothelium and COVID-19: An Increasingly Clear Link Brief Title: Endotheliopathy in COVID-19. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 6196	6.3	3
4	Presence of Coronary Endothelial Dysfunction, Coronary Vasospasm, and Adenosine-Mediated Vasodilatory Disorders in Patients With Ischemia and Nonobstructive Coronary Arteries. <b>2022</b> , 15,		0
3	Sustained Activation of CLR/RAMP Receptors by Gel-Forming Agonists. <b>2022</b> , 23, 13408		0
2	Coronary microvascular dysfunction: A review of recent progress and clinical implications. 10,		1
1	Benefit and risk evaluation of quinapril hydrochloride. 1-7		0